MIFH
DMRA

Migdal Insurance & Financial Holdings’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-125
Closed -$10K – 639
2021
Q4 		$10K Sell
125
-291
-70% -$22.9K ﹤0.01% 596
2021
Q3 		$37K Buy
+416
New +$44.5K ﹤0.01% 491

Other funds holding DMRA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Migdal Insurance & Financial Holdings's DMRA Position: Q1 2022 in Review

Migdal Insurance & Financial Holdings sold out of Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q1 2022, closing a stake of 125 shares — an estimated $10K sold.

Migdal Insurance & Financial Holdings first reported a position in DMRA in Q3 2021 and held it in 2 quarters. The position peaked at $37K in Q3 2021. 25 funds tracked by Wall St. Rank hold DMRA as of Q1 2022.

  • Migdal Insurance & Financial Holdings reported no remaining Damora Therapeutics, Inc. Ordinary Shares position as of Q1 2022 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 125 Damora Therapeutics, Inc. Ordinary Shares shares in Q1 2022, an estimated $10K.
  • Migdal Insurance & Financial Holdings first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q3 2021 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Damora Therapeutics, Inc. Ordinary Shares position peaked at $37K in Q3 2021.
  • 25 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q1 2022.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2022, filed 2 May 2022.